GY
Therapeutic Areas
Taiwan Liposome Company Pipeline
| Drug | Indication | Phase |
|---|---|---|
| TLC599 | Osteoarthritis knee pain | Phase 3 |
| TLC590 | Metabolic disorders | Phase 2 |
| TLC502 | Immune disorders | Preclinical |
| TLC501 | Metabolic and immune disorders | Preclinical |
| TLC518 | Type‑2 diabetes (once‑monthly GLP‑1) | Phase 2/3 |
| tLNP CAR‑T | Infectious diseases / regenerative medicine | Preclinical |
| Ampholipad | Post‑surgical pain | Commercial (China) |
Leadership Team at Taiwan Liposome Company
DK
Dr. Keelung Hong
Chairman
TG
Tina Guilder
Chief Strategy Officer & President of US Operations
GS
George Spencer‑Green
Chief Medical Officer
AS
Amanda Sung
Head of Finance
VC
Vincent Chang
Vice President, CMC & QA
SF
Sheue Fang Shih
Vice President, Product Development
YT
Yunlong Tseng
Vice President, Research & Development